Loading...
OTCM
INTI
Market cap8mUSD
Jul 17, Last price  
0.05USD
1D
-2.04%
1Q
20.00%
Jan 2017
-87.69%
Name

Inhibitor Therapeutics Inc

Chart & Performance

D1W1MN
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
-14.20%
Rev. gr., 5y
%
Revenues
0k
7,802,8916,532,48212,422,1939,435,4943,272,784610,281000-26,4900000000000
Net income
-3m
L+10.35%
79,123-1,152,649-2,758,101-9,862,746-2,360,372-1,004,270-227,888186,366-1,835,056-3,975,298-3,949,585-7,000,217-5,101,165-4,550,230-2,718,816-1,056,861-313,46912,106,230-3,026,135-3,339,201
CFO
-3m
L+19.73%
1,007,75777,074-867,728-1,366,425214,553-173,80767,533-464,266-1,223,615-1,303,524-2,263,716-3,758,548-2,913,082-3,708,266-2,705,719-825,357-220,43311,740,598-2,700,312-3,233,049
Earnings
Aug 04, 2025

Profile

Inhibitor Therapeutics, Inc., a pharmaceutical development company, develops and commercializes therapeutics for patients with certain cancers and non-cancerous proliferation disorders in the United States. It engages in the development of therapies for prostate and lung cancer utilizing SUBA-Itraconazole, an oral formulation of the drug itraconazole; and conducted a positive Phase 2b study of SUBA-Itraconazole for the treatment of basal cell carcinoma nevus syndrome. The company was formerly known as HedgePath Pharmaceuticals, Inc. and changed its name to Inhibitor Therapeutics, Inc. in August 2019. Inhibitor Therapeutics, Inc. was founded in 1992 and is based in Tampa, Florida.
URL
https://inhibitortx.com/
IPO date
Mar 05, 1996
Employees
3
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
3,657
3,405
658
Unusual Expense (Income)
NOPBT
(3,657)
(3,405)
(658)
NOPBT Margin
Operating Taxes
55
Tax Rate
NOPAT
(3,657)
(3,405)
(713)
Net income
(3,339)
10.35%
(3,026)
-125.00%
12,106
-3,962.02%
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
411
Long-term debt
Deferred revenue
3,000
3,000
Other long-term liabilities
3,000
Net debt
(5,607)
(8,840)
(11,540)
Cash flow
Cash from operating activities
(3,233)
(2,700)
11,741
CAPEX
2
Cash from investing activities
Cash from financing activities
(411)
180
FCF
(3,657)
(3,405)
(1,103)
Balance
Cash
5,607
8,840
11,951
Long term investments
Excess cash
5,607
8,840
11,951
Stockholders' equity
(52,102)
(48,763)
(45,737)
Invested Capital
57,087
57,047
57,444
ROIC
ROCE
EV
Common stock shares outstanding
172,263
171,950
367,777
Price
0.06
-34.67%
0.09
-6.84%
0.10
-34.06%
Market cap
10,353
-34.56%
15,819
-56.44%
36,318
-35.54%
EV
4,746
6,979
24,778
EBITDA
(3,657)
(3,405)
(658)
EV/EBITDA
Interest
23
Interest/NOPBT